Exploring the Impact of Palmitoylated PrRP31 and Liraglutide in Mouse Model of Obesity and MASLD

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F25%3A00638937" target="_blank" >RIV/61388963:_____/25:00638937 - isvavai.cz</a>

Výsledek na webu

<a href="https://hdl.handle.net/11104/0369482" target="_blank" >https://hdl.handle.net/11104/0369482</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Exploring the Impact of Palmitoylated PrRP31 and Liraglutide in Mouse Model of Obesity and MASLD

Popis výsledku v původním jazyce

Obesity and type 2 diabetes are key factors leading to metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by fat accumulation in the liver. Anorexigenic peptides such as glucagon-like peptide 1 (GLP-1), its long-acting analogue liraglutide (LIRA), and prolactin-releasing peptide (PrRP) show promise for both obesity and MASLD treatment. Lipidization of peptides allows them to act centrally after peripheral administration, which have been shown in recent studies for palmitoylated PrRP31 (palm11-PrRP31). This study aims to investigate effects of palm11-PrRP31 and LIRA on a mouse model of obesity and MASLD. nMice with monosodium glutamate (MSG)-induced obesity, fed a high fat, high fructose and high cholesterol diet (FFC) or standard diet (STD) were used, while NMRI mice on either FFC or STD diet served as controls. MSG mice on FFC diet exhibited notable increases in body weight and liver weight, as well as elevated levels of leptin and CRP in plasma. Liver histology revealed a significant increase in the percentage of fat droplets and collagen in FFC diet mice, suggesting signs of fibrosis. After a period of seven months, a one-month intervention with palm11-PrRP31 and LIRA followed. Although body weight did not change significantly, there was a slight decrease in leptin level and a significant decrease in CRP level. Most importantly, a significant decrease in the percentage of fat droplets in the liver was observed after the treatment and the percentage of collagen in the liver was notably lower in the treated mice. nThe findings suggest that anorexigenic peptides may have potential for treating MASLD. However, further studies are required to determine the mechanism of action for its potential application. n

Název v anglickém jazyce

Exploring the Impact of Palmitoylated PrRP31 and Liraglutide in Mouse Model of Obesity and MASLD

Popis výsledku anglicky

Obesity and type 2 diabetes are key factors leading to metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by fat accumulation in the liver. Anorexigenic peptides such as glucagon-like peptide 1 (GLP-1), its long-acting analogue liraglutide (LIRA), and prolactin-releasing peptide (PrRP) show promise for both obesity and MASLD treatment. Lipidization of peptides allows them to act centrally after peripheral administration, which have been shown in recent studies for palmitoylated PrRP31 (palm11-PrRP31). This study aims to investigate effects of palm11-PrRP31 and LIRA on a mouse model of obesity and MASLD. nMice with monosodium glutamate (MSG)-induced obesity, fed a high fat, high fructose and high cholesterol diet (FFC) or standard diet (STD) were used, while NMRI mice on either FFC or STD diet served as controls. MSG mice on FFC diet exhibited notable increases in body weight and liver weight, as well as elevated levels of leptin and CRP in plasma. Liver histology revealed a significant increase in the percentage of fat droplets and collagen in FFC diet mice, suggesting signs of fibrosis. After a period of seven months, a one-month intervention with palm11-PrRP31 and LIRA followed. Although body weight did not change significantly, there was a slight decrease in leptin level and a significant decrease in CRP level. Most importantly, a significant decrease in the percentage of fat droplets in the liver was observed after the treatment and the percentage of collagen in the liver was notably lower in the treated mice. nThe findings suggest that anorexigenic peptides may have potential for treating MASLD. However, further studies are required to determine the mechanism of action for its potential application. n

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů